Remove Clinical Development Remove Pharma Companies Remove Pharmaceuticals
article thumbnail

The Power of AI in Drug Discovery and Development

The Connected Lab

It is reported that every one of the major pharmaceutical companies has announced a partnership with at least one AI-based drug development company, but how is AI being used to facilitate drug development? A Tough Road: Cost To Develop One New Drug Is $2.6 How is AI being applied in Drug Discovery efforts?

article thumbnail

Pfizer CMO Steps Down, Stanford Professor to Transition into Role

The Pharma Data

Rothenberg did not provide any information as to what his next role may be – whether he will take over the helm of a pharma company or assume a role on one or more boards of directors. Rothenberg took over as Pfizer CMO in January 2019, but spent more than 12 years in total working for the pharmaceutical giant.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Women in STEM with Gilda Ascione

Drug Target Review

Following clinical practice, I transitioned to the world of pharmaceutical companies which also had its challenges as I had to learn everything from scratch and use my experience and knowledge differently. Being a doctor means giving courage and hope day in, day out to those experiencing illness.

Doctors 97
article thumbnail

BioSpace Movers & Shakers, Dec. 18

The Pharma Data

Hartfield previously served as CEO of Vitae Pharmaceuticals prior to its acquisition by Allergan. X4 Pharmaceuticals – Diego Cadavid was named chief medical officer of Boston-based X4 Pharmaceuticals. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.

article thumbnail

Ultimovacs ASA Initiates FOCUS Phase II Trial for Universal Cancer Vaccine, UV1, in Head and Neck Cancer Patients Receiving Pembrolizumab

The Pharma Data

The FOCUS trial is Ultimovacs’ fourth Phase II clinical trial with UV1 and comes in addition to the collaboration Phase II trial announced in May 2020. “We To date, UV1 has been tested in four phase I clinical trials in a total of 82 patients and maintained a positive safety and tolerability profile as well as encouraging signals of efficacy.

Vaccine 52
article thumbnail

What type of R&D efforts are needed to develop value added medicines?

Altus Drug Development

Ensuring access to safe and effective treatments is the main challenge faced by pharmaceutical companies big and small. Value-added medicines offer an efficient method to meet the needs of patients while stimulating innovation in the pharmaceutical industry. What R&D efforts are needed to develop value-added medicines?

article thumbnail

Tackling complex manufacturing challenges in modern drug development

Drug Target Review

Daniel Galbraith, Chief Scientific Officer at Solvias , brings extensive expertise in the pharmaceutical and biotechnology sectors. In his role, he provides both strategic and technical guidance to Solvias, a global Contract Research Organisation (CRO) that offers critical analytical services to the pharmaceutical industry.